IP Library › Granted Patent US 9,522,157
Granted Patent B2
US 9,522,157 · App. 15/074,367 · Granted Dec 20, 2016

Osteoclast inhibitors for knee conditions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,522,157
App. No.
15/074,367
Granted
Dec 20, 2016
Kind
B2
Abstract

Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.

Claims (36)

1. A method of treating moderate to severe knee pain comprising administering an inhibitor of osteoclast activity to a person suffering from moderate to severe knee pain,

wherein the person is selected for having a pain intensity of 5 or greater measured using the 0-10 NRS or 5 cm or greater using the 10 cm VAS; and

wherein the inhibitor of osteoclast activity is olpadronic acid, alendronic acid, or incadronic acid.

2. The method of claim 1 , wherein the person suffering from moderate to severe knee pain has a normal joint space in the knee.

3. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered at least twice.

4. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered about every three months, or more frequently.

5. The method of claim 1 , wherein the patient experiences pain relief within about three months after the inhibitor of osteoclast activity is administered to the patient.

6. The method of claim 5 , wherein the patient experiences pain relief for at least 24 hours after the inhibitor of osteoclast activity is administered to the patient.

7. The method of claim 1 , wherein the inhibitor of osteoclast activity is olpadronic acid.

8. The method of claim 1 , wherein the inhibitor of osteoclast activity is alendronic acid.

9. The method of claim 1 , wherein the inhibitor of osteoclast activity is incadronic acid.

10. The method of claim 1 , wherein the patient experiences a reduction in pain intensity—when using a 10 cm visual analog scale—of at least about 0.5.

11. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered at least twice within a period of two months.

12. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered daily, weekly, or monthly.

13. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered at least twice within consecutive daily to monthly time periods.

14. The method of claim 1 , wherein the inhibitor of osteoclast activity is olpadronic acid and about 1000 mg to about 2000 mg of olpadronic acid is orally administered.

15. The method of claim 1 , wherein the inhibitor of osteoclast activity is alendronic acid and about 100 mg to about 1200 mg of alendronic acid is orally administered.

16. The method of claim 1 , wherein the inhibitor of osteoclast activity is incadronic acid and about 5 mg to about 20 mg of incadronic acid is orally administered.

17. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered orally or intravenously.

18. A method of treating moderate knee pain comprising administering an inhibitor of osteoclast activity to a person suffering from moderate knee pain,

wherein the person is selected for having a pain intensity of about 4 to about 7 measured using the 0-10 NRS or about 4 cm to about 7 cm using the 10 cm VAS; and

wherein the inhibitor of osteoclast activity is olpadronic acid, alendronic acid, or incadronic acid.

19. The method of claim 18 , wherein the inhibitor of osteoclast activity is administered daily, weekly, or monthly.

20. The method of claim 18 , wherein the pain is associated with inflammatory or musculoskeletal pain.

21. The method of claim 18 , wherein the patient experiences pain relief for at least 24 hours after the inhibitor of osteoclast activity is administered to the patient.

22. The method of claim 18 , wherein the inhibitor of osteoclast activity is administered orally or intravenously.

23. The method of claim 18 , wherein the osteoclast inhibitor is orally administered daily for about one to about fifteen days.

24. A method of treating severe knee pain comprising administering an inhibitor of osteoclast activity to a person suffering from severe knee pain,

wherein the person is selected for having a pain intensity of about 7 or greater measured using the 0-10 NRS or about 7 cm or greater using the 10 cm VAS; and

wherein the inhibitor of osteoclast activity is olpadronic acid, alendronic acid, or incadronic acid.

25. The method of claim 24 , wherein the severe knee pain is associated with musculoskeletal or inflammatory pain.

26. The method of claim 24 , wherein the inhibitor of osteoclast activity is administered daily, weekly, or monthly.

27. The method of claim 24 , wherein each dose of the inhibitor of osteoclast activity is between about 5 mg and about 300 mg.

28. The method of claim 24 , wherein the inhibitor of osteoclast activity is orally administered once daily for at least five days.

29. The method of claim 24 , wherein the inhibitor of osteoclast activity is orally administered once weekly for at least four weeks.

30. The method of claim 24 , wherein the inhibitor of osteoclast activity is orally administered once monthly for at least two months.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2016
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 039103/0203 →